



BLA 761291/S-017
BLA 761342/S-019

SUPPLEMENT APPROVAL

Janssen Biotech, Inc.
c/o Janssen Research & Development, LLC
Attention: Raja Agnihotram and Miranda Johnson, Ph.D.
920 US Highway 202, P.O. Box 300
Raritan, NJ 08869

Dear Mr. Agnihotram and Dr. Johnson:

Please refer to your supplemental biologics license applications (sBLAs) received November 7, 2025, and your amendments, submitted under section 351(a) of the Public Health Service Act for Tecvayli (teclistamab-cqyv) and Talvey (talquetamab-tgvs) injections for subcutaneous use.

These Prior Approval sBLAs provide for proposed modifications to the approved Tecvayli and Talvey risk evaluation and mitigation strategy (REMS).

We have completed our review of these supplemental applications, as amended. They are approved effective on the date of this letter.

RISK EVALUATION AND MITIGATION STRATEGY (REMS) REQUIREMENTS

The REMS for Tecvayli was originally approved on October 25, 2022, and the combined Tecvayli and Talvey REMS was approved on August 9, 2023. The most recent REMS modification was approved on March 5, 2026. The Tecvayli and Talvey REMS consists of elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS.

Your proposed modification to the REMS consists of an update to the REMS Dispense Authorization (RDA) requirement to reduce administrative burden on pharmacies and healthcare settings.

Your proposed modified REMS, submitted on November 7, 2025, amended and appended to this letter, is approved.

The timetable for submission of assessments of the REMS remains the same as that approved on August 9, 2023.

The revised REMS assessment plan must include, but is not limited to, the following:

For each metric, the two previous, current, and cumulative reporting periods (where applicable) unless otherwise noted will be reported.

Program Implementation and Operations

1. Program Implementation

a. Date the REMS Website went live

- i. Number of total visits and unique visits to the REMS Website
- ii. Number and type of REMS materials downloaded or accessed

b. Date prescribers and pharmacies/healthcare settings were able to complete the REMS certification process (online and by fax)

2. REMS Certification and Enrollment Statistics

a. Healthcare Providers

- i. Number of newly certified healthcare providers and the number and percentage of active (i.e., for whom a REMS Dispense Authorization for Tecvayli or Talvey has been generated at least once during the current reporting period, previous reporting period, and cumulatively), stratified by:

1. Credentials (e.g., Doctor of Medicine, Doctor of Osteopathic Medicine, Nurse Practitioner, Physician Assistant, other)
2. Specialty (e.g., Oncology, Hematology, Internal Medicine/Family Medicine, Other). If "other" accounts for >10% of respondents for specialties, provide the most common specialties identified.
3. Geographic region as defined by the US Census
4. Method of enrollment (e.g., online, fax, e-mail) for newly certified healthcare providers only

- ii. Number of incomplete prescriber enrollments, and summary of reported reason(s) for not completing

b. Pharmacies and Healthcare Settings

- i. Number of newly certified pharmacies/healthcare settings and the number and percentage of active (i.e., who have dispensed or ordered the drug at least once during the current reporting period, previous reporting period, and cumulatively) pharmacies/healthcare settings stratified by:

1. Type of pharmacy/healthcare setting (e.g., Inpatient Hospital Pharmacy, Outpatient Hospital Pharmacy, Oncology Infusion Center, Community Oncology)

Physician Office, Other). If “other” accounts for > 10% of respondents for type, provide the most common type(s) identified.

2. Geographic region as defined by the US Census
3. Method of enrollment (e.g., online, fax, e-mail) for newly certified pharmacies/healthcare settings only

- ii. Number of incomplete pharmacy/healthcare setting enrollments, and summary of reported reason(s) for not completing

c. Wholesalers/distributors

- i. Number of wholesalers/distributors contracted to ship and the number of active (i.e., who have shipped at least once during the current reporting period, previous reporting period, and cumulatively) wholesalers/distributors

3. Utilization Data

- a. Number of vials sent to certified pharmacies/healthcare settings, stratified by each drug and by type of pharmacy/healthcare setting
- b. Number and percentage of healthcare providers for whom at least one REMS Dispense Authorization (RDA) code was generated, stratified, for each drug, by medical specialty (e.g., oncology) and provider credentials (e.g., Doctor of Medicine)
- c. Number of all RDAs successfully generated, stratified by pharmacy/healthcare setting type
- d. Number of RDAs successfully generated for a prescription that was written by a prescriber who hasn't had a Tecvayli or Talvey prescription filled by that pharmacy or healthcare setting before
- e. Number of RDAs rejected, stratified by each drug:
 - i. Reasons and number of denials (numerator) divided by all denials (denominator)

1. Healthcare provider (HCP) not certified.

IX. Number of HCPs that became certified following the RDA rejection

2. Other reasons for denial not categorized above

- ii. Number of rejected RDAs that were subsequently authorized

4. REMS Compliance

a. Audits

- i. A copy of the audit plan

- ii. Report of audit findings for each stakeholder
 - iii. Number of audits expected, and the number of audits performed
 - iv. Documentation of completion of training for relevant staff
 - v. Documentation of processes and procedures in place for complying with the REMS
 - vi. Verification for each audited stakeholder's site that the designated Authorized Representative remains the same. If different, include the number of new Authorized Representatives
 - vii. Number and type of deficiencies (e.g., critical, major, or minor findings) noted for each group of audited stakeholders as a percentage of audited stakeholders
 - viii. Confirmation of documentation of completion of training for relevant staff after audit findings indicated training was necessary
 - ix. A comparison of the findings to findings of previous audits and an assessment of whether any trends are observed
- b. A copy of the Noncompliance Plan which addresses the criteria for noncompliance for each stakeholder (healthcare providers, pharmacies/healthcare settings and wholesalers-distributors), actions taken to address noncompliance for each event, and under what circumstances a stakeholder would be suspended or decertified from the REMS
- i. For those with deficiencies noted, report the number that successfully completed a Corrective and Preventive Actions (CAPA) plan within the timeframes specified in the Noncompliance Plan
 - ii. For any that did not complete the CAPA within the timeframe specified in the Noncompliance Plan, describe actions taken
 - iii. Number of instances of noncompliance accompanied by a description of each instance and the reason for the occurrence (if provided). For each instance of noncompliance, report the following information:
 - 1. Unique ID(s) of the stakeholder(s) associated with the noncompliance event or deviation to enable tracking over time
 - 2. Source of the noncompliance data
 - 3. Results of root cause analysis

4. Action(s) that were taken in response

iv. Pharmacies/healthcare settings

1. Number of pharmacies/healthcare settings for which non-compliance with the REMS is detected (numerator) divided by all pharmacies/healthcare settings dispensing Tecvayli or Talvey (denominator)
2. Number and description of pharmacies/healthcare settings that dispensed Tecvayli or Talvey to non-certified prescribers, and any corrective and preventative actions (CAPA) taken to prevent future occurrences
3. Number and description of pharmacies/healthcare settings that dispensed a prescription that was written by a prescriber who hasn't had a Tecvayli or Talvey prescription filled by that pharmacy or healthcare setting before, without obtaining a REMS Dispense Authorization (RDA) code, and any CAPA taken to prevent future occurrences. Provide the source of the noncompliance data.
4. Number and description of prescriptions dispensed without obtaining an RDA code, that were written by a prescriber who hasn't had a Tecvayli or Talvey prescription filled by that pharmacy or healthcare setting before. Describe root cause analyses for events, and any CAPAs completed. Provide source of the noncompliance data.
5. Number of non-certified pharmacies/healthcare settings that dispensed Tecvayli or Talvey (numerator) divided by all pharmacies/healthcare settings that dispensed Tecvayli or Talvey
6. Number of prescriptions dispensed by non-certified pharmacies/healthcare settings (numerator) divided by all Tecvayli and Talvey prescriptions dispensed (denominator) and the actions taken to prevent future occurrences
7. Summary of audit findings and any action taken and outcome of actions to prevent future occurrences
8. Summary of findings for monitoring conducted during the reporting period, including any CAPA

v. Wholesalers/Distributors

1. Number and description of non-certified pharmacies/healthcare settings that were shipped Tecvayli or Talvey, and the number of these that subsequently became certified
 2. The number of authorized wholesalers-distributors for which non-compliance with the REMS is detected (numerator) divided by the number of contracted wholesalers-distributors (denominator)
 3. The number and type of wholesalers-distributors not contracted with Janssen that shipped Tecvayli or Talvey, the number of incidents for each, actions taken to remove Tecvayli or Talvey from these entities, actions taken to prevent future occurrences, and outcomes of such actions
 4. The number of contracted wholesalers-distributors suspended and/or unauthorized to distribute for non-compliance with REMS requirements, reasons for such actions and actions taken to prevent distribution or removal of Tecvayli or Talvey from these entities
- c. Number of Patient Wallet Cards that were ordered for dissemination to healthcare providers, stratified by language (English, Mandarin, Spanish)
 - d. Number of Patient Wallet Cards that were downloaded from the REMS Website, stratified by language (English, Mandarin, Spanish)
 - e. Any other Tecvayli and Talvey REMS noncompliance, source of report and resulting CAPA
5. REMS Coordinating Center Report
 - a. Number of contacts by stakeholder type (patient/caregiver, certified prescriber, pharmacy/healthcare setting authorized representative or staff, other HCP, wholesaler/distributor, other)
 - b. Summary of the reasons for the call(s) by stakeholder type. Limit the summary to the top five reasons for calls by stakeholder group
 - c. Description of each call, including stakeholder credentials, that may indicate an issue with product access due to the REMS program, REMS program burden or adverse event
 - d. If the summary reason for the call(s) indicates an adverse event related to Cytokine Release Syndrome (CRS) or neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), include details and the outcome of the call(s)

- e. Provide an assessment for any reports to the REMS Coordinating Center indicating a burden to the healthcare system or barrier(s) to patient access. Include in the assessment whether the burden or access issue is attributable to the REMS, insurance, health care availability, other
- f. Summary of frequently asked questions (FAQ) by stakeholder credentials type. Limit the summary to the top five FAQs for calls by stakeholder group
- g. Summary of any noncompliance that is identified through coordinating center contacts, source of report and resulting CAPA
- h. Summary of CAPAs resulting from issues identified
- i. Percentage of calls to the REMS Coordinating Center that were answered within 20 minutes
- j. The shortest wait time for a call to be answered, the longest wait time for a call to be answered and the median time for a call to be answered
- k. Percentage of calls to the REMS Coordinating Center where the caller abandoned the call before the call was answered
- l. The shortest wait time at which a call was abandoned, the longest wait time before the call was abandoned and the median wait time for a call to be abandoned

Knowledge

6. Knowledge Assessment

- a. Number of completed healthcare provider Knowledge Assessments, including the method of completion
- b. Summary statistics, including mean number of attempts, score, and range of scores and number of attempts to successfully complete the Knowledge Assessment
- c. Summary of most frequently missed questions on the Knowledge Assessment
- d. A summary of potential comprehension or perception issues identified with the Knowledge Assessment

7. Periodic Survey of Certified Prescribers (beginning with the 1-Year REMS Assessment Report and thereafter with each assessment report)

A Healthcare Provider (HCP) REMS Survey will be conducted with random samples of healthcare providers who prescribe Tecvayli or Talvey

- a. Evaluation of understanding of the risks for CRS and neurologic toxicity, including ICANS, associated with Tecvayli and Talvey use and

mitigation strategies of the Tecvayli and Talvey REMS as well as compliance with the mitigation strategies

- b. An evaluation of prescriber's knowledge on the importance of monitoring patients for signs and symptoms of CRS and neurologic toxicity, including ICANS
 - c. Provide the proportion of HCP REMS Survey respondents that demonstrated knowledge of the importance of monitoring patients for signs and symptoms of CRS and neurologic toxicity, including ICANS
8. Periodic Survey of Patients (beginning with the 5-Year REMS Assessment Report and thereafter with each assessment report)

A Patient REMS Survey will be conducted with random samples of patients who receive Tecvayli or Talvey to assess receipt of prescriber counseling and the Patient Wallet Card prior to treatment initiation (first dose).

Health Outcomes and/or Surrogates of Health Outcomes

9. A summary analysis of all reported cases of CRS and neurologic toxicity, including ICANS, stratified by source of report (i.e., spontaneous)
 - a. Include the following stratifications by grade/severity in the analysis
 - i. Step-up dosing was initiated in the hospital setting. (For those reports that indicate initiation outside of the hospital setting provide the setting if known)
 - ii. Pre-medication was administered

Overall Assessment of REMS Effectiveness

10. The requirements for assessments of an approved REMS under section 505-1(g)(3) include with respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether one or more such goals or such elements should be modified.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use, as described in section 505-1(g)(2)(A) of the FDCA. This assessment should include:

- a) An evaluation of how the benefit-risk profile will or will not change with the new indication.

- b) A determination of the implications of a change in the benefit-risk profile for the current REMS.
- c) *If the new indication for use introduces unexpected risks:* A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.
- d) *If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* A statement about whether the REMS was meeting its goals at the time of that last assessment and if any modifications of the REMS have been proposed since that assessment.
- e) *If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* Provision of as many of the currently listed assessment plan items as is feasible.
- f) *If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including:* Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. *If you are not proposing REMS modifications,* provide a rationale for why the REMS does not need to be modified.

Additionally, we recommend that you submit your proposed audit plan and noncompliance plan for FDA review within 60 days of this letter. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters, at the top of your cover letter and at the top of the first page of the main submission document: **“REQUEST FOR REMS ASSESSMENT METHODOLOGY PROTOCOL REVIEW/ AUDIT AND NONCOMPLIANCE PLAN”**.

We recommend that you submit your protocol for the patient survey(s) for FDA review within 90 days of this letter. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters, at the top of your cover letter and at the top of the first page of the main submission document: **“REQUEST FOR REMS ASSESSMENT METHODOLOGY PROTOCOL REVIEW/ SURVEY METHODOLOGIES.”**

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at

least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted.

Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

BLA ##### REMS ASSESSMENT METHODOLOGY PROTOCOL REVIEW
(insert concise description of content in bold capital letters, e.g.,
SURVEY METHODOLOGIES, AUDIT PLAN, NONCOMPLIANCE PLAN, DRUG USE STUDY)

An unbranded biological product under this BLA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an unbranded biological product under this BLA, contact us to discuss what will be required in the unbranded biological product REMS submission.

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

BLA ##### REMS ASSESSMENT

or

**NEW SUPPLEMENT FOR BLA #####/S-000
CHANGES BEING EFFECTED IN 30 DAYS
PROPOSED MINOR REMS MODIFICATION**

or

**NEW SUPPLEMENT FOR BLA #####/S-000
PRIOR APPROVAL SUPPLEMENT
PROPOSED MAJOR REMS MODIFICATION**

or

**NEW SUPPLEMENT FOR BLA #####/S-000
PRIOR APPROVAL SUPPLEMENT
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING
CHANGES SUBMITTED IN SUPPLEMENT XXX**

or

**NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR BLA #####/S-000
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

REMS REVISIONS FOR BLA #####

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word and PDF format. If certain documents, such as enrollment forms, or website screenshots are only in PDF format, they may be submitted as such, but Word and PDF format are preferred.

SUBMISSION OF REMS DOCUMENT IN SPL FORMAT

As soon as possible, but no later than 14 days from the date of this letter, submit the REMS document in Structured Product Labeling (SPL) format using the FDA automated drug registration and listing system (eLIST). Content of the REMS document must be identical to the approved REMS document. The SPL will be publicly available.

Information on submitting REMS in SPL format may be found in the guidance for industry *Providing Regulatory Submission in Electronic Format – Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling*.

For more information on submitting REMS in SPL format, please email FDAREMSwebsite@fda.hhs.gov.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplement application, you are exempt from this requirement.

BLA 761291/S-017

BLA 761342/S-019

Page 12

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Jessica Kim, Safety Regulatory Project Manager, at 240-402-0883, or via email at Jessica.Kim1@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Oladimeji Akinboro, M.D., M.P.H
Associate Director for Safety
Office of Oncologic Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- REMS

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

OLADIMEJI A AKINBORO
05/06/2026 03:39:30 PM